Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
473 questions in 36 reviews · HIV/AIDS
current versionsNo studies 38 · 8%Ungraded 9 · 1.9%Very low 126 · 26.6%Low 127 · 26.8%Moderate 152 · 32.1%High 21 · 4.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
An extended NVP regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1week) HIV Transmission or Death at 24 months among those uninfected at birth11 · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | HR 0.71 [0.58, 0.87] | 1 study · 1129 participants | Moderate |
An extended NVP regimen administered to infants for 28 weeks vs 1 week of antiretroviral prophylaxis HIV transmission at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | RR 0.29 [0.15, 0.56] | 1 study · 1447 participants | Low |
An extended NVP regimen administered to infants for 28 weeks vs 1 week of antiretroviral prophylaxis Infant mortality at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | RR 0.62 [0.28, 1.35] | 1 study · 1520 participants | Low |
An extended NVP regimen administered to infants for 28 weeks vs 1 week of antiretroviral prophylaxis HIV transmission or death at 28 weeks among those whose diagnostic test was negative at 2 weeks · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | RR 0.38 [0.22, 0.65] | 1 study · 1447 participants | Moderate |
An extended NVP regimen administered to infants for 28 weeks vs 1 week of antiretroviral prophylaxis Infants with Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | RR 1.25 [0.97, 1.61] | 1 study · 1520 participants | Low |
A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered HIV transmission at 12 months among infants whose HIV diagnostic testing was negative within 6 weeks of birth and whose mothers were not on HAART · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | HR 0.65 [0.33, 1.28] | 1 study · 1078 participants | Low |
A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered HIV transmission at 12 months among all infants whose HIV diagnostic testing was negative within 6 weeks of birth · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | HR 0.66 [0.34, 1.27] | 1 study · 1512 participants | Low |
A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered Infant mortality at 12 months among all those whose HIV diagnostic testing was negative within 6 weeks of birth · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | HR 0.75 [0.41, 1.35] | 1 study · 1522 participants | Low |
A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered HIV transmission or death at 12 months among all infants whose HIV diagnostic testing was negative within 6 weeks of birth · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | HR 0.66 [0.42, 1.05] | 1 study · 1522 participants | Moderate |
A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered Infants with Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | RR 1 [0.95, 1.05] | 1 study · 1519 participants | High |
A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered HIV transmission at 6 months among infants whose HIV diagnostic testing was negative within 6 weeks of birth and whose mothers were not on HAART · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | HR 0.41 [0.18, 0.9] | 1 study · 1078 participants | Low |
An extended NVP regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1week) Infants with possible related Severe Adverse Events ‐ 24 months11 · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | RR 1.06 [0.7, 1.59] | 1 study · 2019 participants | Very low |
A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered HIV transmission at 6 months among all infants whose HIV diagnostic testing was negative within 6 weeks of birth · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | HR 0.46 [0.21, 0.99] | 1 study · 1512 participants | Low |
A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered Infant mortality at 6 months among all those whose HIV diagnostic testing was negative within 6 weeks of birth · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | HR 0.44 [0.21, 0.95] | 1 study · 1522 participants | Low |
A once‐daily NVP regimen administered for 6 months vs a once‐daily NVP regimen administered HIV transmission or death at 6 months among all infants whose HIV diagnostic testing was negative within 6 weeks of birth · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | HR 0.7 [0.38, 1.31] | 1 study · 1522 participants | Low |
An extended antiretroviral regimen administered to mothers for 28 weeks vs an extended NVP regimen administered to infants HIV transmission at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth · HIV‐infected mothers and their breastfeeding infants Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | RR 1.78 [0.88, 3.59] | 1 study · 1618 participants | Moderate |
An extended antiretroviral regimen administered to mothers for 28 weeks vs an extended NVP regimen administered to infants Infant mortality at 28 weeks among those whose diagnostic testing was negative at 2 weeks after birth · HIV‐infected mothers and their breastfeeding infants Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | RR 1.09 [0.48, 2.47] | 1 study · 1701 participants | Moderate |
An extended antiretroviral regimen administered to mothers for 28 weeks vs an extended NVP regimen administered to infants HIV transmission or death at 28 weeks among those whose diagnostic test was negative at 2 weeks · HIV‐infected mothers and their breastfeeding infants Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | RR 1.6 [0.91, 2.82] | 1 study · 1618 participants | Moderate |
An extended antiretroviral regimen administered to mothers for 28 weeks vs an extended NVP regimen administered to infants Infants with Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | RR 0.89 [0.71, 1.12] | 1 study · 1701 participants | Low |
An extended antiretroviral regimen administered to mothers for 28 weeks vs an extended NVP regimen administered to infants Mothers with Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | RR 2.8 [1.53, 5.11] | 1 study · 1701 participants | Low |
An extended NVP regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1week) Infants with Probably Related Severe Adverse Events11 · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | RR 2.96 [0.6, 14.64] | 1 study · 2019 participants | Very low |
An extended NVP plus ZDV regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1 week) HIV Transmission at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | HR 0.65 [0.48, 0.88] | 1 study · 2000 participants | Moderate |
Balanced nutritional supplement vs counselling or nutritional placebo Energy intake (kcal/day) · patients with reducing morbidity and mortality in people with HIV Nutritional interventions for reducing morbidity and mortality in people with HIV (2013) · Cochrane | no estimate extracted | 3 studies · 131 participants | Low |
Balanced nutritional supplement vs counselling or nutritional placebo Protein intake (g/day) · patients with reducing morbidity and mortality in people with HIV Nutritional interventions for reducing morbidity and mortality in people with HIV (2013) · Cochrane | no estimate extracted | 2 studies · 81 participants | Low |
Balanced nutritional supplement vs counselling or nutritional placebo Body weight · patients with reducing morbidity and mortality in people with HIV Nutritional interventions for reducing morbidity and mortality in people with HIV (2013) · Cochrane | no estimate extracted | 4 studies · 233 participants | Moderate |
Balanced nutritional supplement vs counselling or nutritional placebo Fat mass measured in % of TBW · patients with reducing morbidity and mortality in people with HIV Nutritional interventions for reducing morbidity and mortality in people with HIV (2013) · Cochrane | no estimate extracted | 4 studies · 233 participants | Moderate |
Balanced nutritional supplement vs counselling or nutritional placebo Fat free mass · patients with reducing morbidity and mortality in people with HIV Nutritional interventions for reducing morbidity and mortality in people with HIV (2013) · Cochrane | no estimate extracted | 3 studies · 218 participants | Low |
Balanced nutritional supplement vs counselling or nutritional placebo CD4 · patients with reducing morbidity and mortality in people with HIV Nutritional interventions for reducing morbidity and mortality in people with HIV (2013) · Cochrane | no estimate extracted | 2 studies · 81 participants | Low |
Balanced nutritional supplement vs counselling or nutritional placebo Viral load (log10 copies/ml) · patients with reducing morbidity and mortality in people with HIV Nutritional interventions for reducing morbidity and mortality in people with HIV (2013) · Cochrane | no estimate extracted | 1 study · 66 participants | Very low |
Co‐formulated abacavir‐lamivudine‐zidovudine vs NNRTIs or PIs Virologic failure 2 successive HIV‐1 RNA >= 200copies/ml at 16+ weeks after randomisation · Antiretroviral‐naive HIV infected patients Co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection and AIDS (2013) · Cochrane | RR 1.14 [0.56, 2.31] | 3 studies · 1687 participants | Moderate |
Co‐formulated abacavir‐lamivudine‐zidovudine vs NNRTIs or PIs Virologic suppression Viral load < 50 copies/ml · Antiretroviral‐naive HIV infected patients Co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection and AIDS (2013) · Cochrane | RR 0.97 [0.75, 1.25] | 4 studies · 2247 participants | Moderate |
Co‐formulated abacavir‐lamivudine‐zidovudine vs NNRTIs or PIs CD4 cell count · Antiretroviral‐naive HIV infected patients Co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection and AIDS (2013) · Cochrane | no estimate extracted | 3 studies · 1687 participants | Moderate |
Co‐formulated abacavir‐lamivudine‐zidovudine vs NNRTIs or PIs Severe adverse events · Antiretroviral‐naive HIV infected patients Co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection and AIDS (2013) · Cochrane | RR 1.22 [0.78, 1.92] | 4 studies · 2247 participants | Moderate |
Co‐formulated abacavir‐lamivudine‐zidovudine vs NNRTIs or PIs Hypersensitivity reactions · Antiretroviral‐naive HIV infected patients Co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection and AIDS (2013) · Cochrane | RR 4.04 [0.41, 40.02] | 4 studies · 2247 participants | Moderate |
Intervention NR Failure (overall) · HIV‐infected adult patients treated with a PI‐containing regimen with undetectable viral load Abacavir‐based triple nucleoside regimens for maintenance therapy in patients with HIV (2013) · Cochrane | RR 0.88 [0.74, 1.04] | 8 studies · 1606 participants | Moderate |
Intervention NR Discontinuation for adverse events · HIV‐infected adult patients treated with a PI‐containing regimen with undetectable viral load Abacavir‐based triple nucleoside regimens for maintenance therapy in patients with HIV (2013) · Cochrane | RR 0.68 [0.44, 1.07] | 8 studies · 1597 participants | Moderate |
Intervention NR Virologic failure · HIV‐infected adult patients treated with a PI‐containing regimen with undetectable viral load Abacavir‐based triple nucleoside regimens for maintenance therapy in patients with HIV (2013) · Cochrane | RR 1.39 [0.95, 2.02] | 8 studies · 1587 participants | Moderate |
Intervention NR Death and AIDS related events · HIV‐infected adult patients treated with a PI‐containing regimen with undetectable viral load Abacavir‐based triple nucleoside regimens for maintenance therapy in patients with HIV (2013) · Cochrane | RR 1.66 [0.62, 4.42] | 4 studies · 1044 participants | Low |
Intervention NR Virologically linked HIV incidence (RCT) · Serodiscordant couples Antiretroviral therapy for prevention of HIV transmission in HIV‐discordant couples (2013) · Cochrane | Rate Ratio 0.04 [0, 0.27] | 1 study · 1750 participants | High |
Intervention NR HIV incidence: low‐/middle‐income countries · Serodiscordant couples Antiretroviral therapy for prevention of HIV transmission in HIV‐discordant couples (2013) · Cochrane | RR 0.53 [0.29, 0.97] | 7 studies · 45029 participants | Low |
Intervention NR HIV incidence: high income countries · Serodiscordant couples Antiretroviral therapy for prevention of HIV transmission in HIV‐discordant couples (2013) · Cochrane | RR 0.77 [0.33, 1.83] | 2 studies · 1061 participants | Very low |
Intervention NR HIV incidence (observational studies) · Serodiscordant couples Antiretroviral therapy for prevention of HIV transmission in HIV‐discordant couples (2013) · Cochrane | Rate Ratio 0.58 [0.35, 0.96] | 9 studies · 46204 participants | Moderate |
Intervention NR HIV incidence (observational studies‐‐sensitivity analysis) · Serodiscordant couples Antiretroviral therapy for prevention of HIV transmission in HIV‐discordant couples (2013) · Cochrane | Rate Ratio 0.36 [0.17, 0.75] | 7 studies · 46560 participants | Moderate |
Intervention NR HIV incidence: CD4 subgroups (<200 cells/µL) (observational studies) · Serodiscordant couples Antiretroviral therapy for prevention of HIV transmission in HIV‐discordant couples (2013) · Cochrane | RR 0.12 [0.02, 0.81] | 5 studies · 26594 participants | Low |
Intervention NR HIV incidence: CD4 subgroups (200‐350 CD4 cells/µL) (observational studies) · Serodiscordant couples Antiretroviral therapy for prevention of HIV transmission in HIV‐discordant couples (2013) · Cochrane | RR 0.66 [0.47, 0.92] | 4 studies · 9595 participants | Very low |
Intervention NR HIV incidence: CD4 subgroups (350 or more CD4 cells/µL) (observational studies) · Serodiscordant couples Antiretroviral therapy for prevention of HIV transmission in HIV‐discordant couples (2013) · Cochrane | RR 0.12 | 3 studies · 13426 participants | Low |
Intervention NR Virologically linked HIV incidence: CD4 subgroups (350 or more CD4 cells/µL) (RCT) · Serodiscordant couples Antiretroviral therapy for prevention of HIV transmission in HIV‐discordant couples (2013) · Cochrane | RR 0.04 [0, 0.27] | 1 study · 1750 participants | High |
Intervention NR HIV incidence: gender subgroup (female cases) · Serodiscordant couples Antiretroviral therapy for prevention of HIV transmission in HIV‐discordant couples (2013) · Cochrane | RR 0.39 [0.13, 1.18] | 3 studies · 15608 participants | Low |
Intervention NR HIV incidence: gender subgroup (male Cases) · Serodiscordant couples Antiretroviral therapy for prevention of HIV transmission in HIV‐discordant couples (2013) · Cochrane | RR 0.11 [0.01, 1.62] | 3 studies · 25073 participants | Low |
Intervention NR ART adherence · People living with HIV infection Telephone delivered interventions for reducing morbidity and mortality in people with HIV infection (2013) · Cochrane | no estimate extracted | 3 studies · 191 participants | Low |